

Kathryn M Lemberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7904778/publications.pdf>

Version: 2024-02-01

7
papers

297
citations

1684188
5
h-index

1720034
7
g-index

7
all docs

7
docs citations

7
times ranked

384
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical development of metabolic inhibitors for oncology. Journal of Clinical Investigation, 2022, 132, .	8.2	59
2	Trainee-led Engagement of the Care Team Improves Application of an Institutional Blood Culture Clinical Decision Algorithm to Pediatric Oncology Inpatients: A Single-institution Quality Improvement Project. Pediatric Quality & Safety, 2022, 7, e545.	0.8	2
3	Glutamine Antagonist GA-607 Causes a Dramatic Accumulation of FGAR which can be used to Monitor Target Engagement. Current Drug Metabolism, 2021, 22, 735-745.	1.2	4
4	The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor. Molecular Cancer Therapeutics, 2020, 19, 397-408.	4.1	18
5	From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor. Genes, 2020, 11, 691.	2.4	30
6	Tumor-Targeted Delivery of 6-Diazo-5-oxo-L-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs. Journal of Medicinal Chemistry, 2019, 62, 3524-3538.	6.4	36
7	We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine. Molecular Cancer Therapeutics, 2018, 17, 1824-1832.	4.1	148